AXSM
Axsome Therapeutics, Inc.
Stock
$179.25−2.82 (−1.55%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $320M | $323M | $315M | $386M | $201M | $86M | $184M | $220M | — | — | — | — | — |
| Inventory | $38M | $28M | $16M | $15M | $4.3M | — | — | — | — | — | — | — | — |
| Current assets | $657M | $589M | $485M | $504M | $246M | $87M | $184M | $220M | $15M | $35M | $38M | $49M | — |
| Goodwill | $12M | $12M | $12M | $12M | $10M | — | — | — | — | — | — | — | — |
| Intangible assets | $37M | $41M | $47M | $53M | $60M | — | — | — | — | — | — | — | — |
| Total assets | $761M | $690M | $568M | $588M | $331M | $88M | $186M | $221M | $15M | $36M | $38M | $49M | — |
| Current liabilities | $460M | $379M | $230M | $139M | $97M | $23M | $23M | $24M | $11M | $12M | $7.2M | $2.6M | — |
| Long-term debt | $118M | $118M | $181M | $178M | $94M | $49M | $48M | $17M | $3.6M | $6.7M | $9.5M | — | — |
| Total liabilities | $678M | $602M | $511M | $397M | $222M | $72M | $72M | $42M | $14M | $19M | $17M | $2.6M | — |
| Shareholders' equity | $83M | $88M | $57M | $191M | $110M | $16M | $114M | $179M | $938K | $17M | $22M | $46M | −$3.2M |
| Shares outstanding | 52.4M | 51.2M | 48.8M | 47.4M | 43.5M | 38.5M | 37.4M | 37.1M | 33.3M | 25.5M | 19.2M | — | — |
| Current ratio | 1.43 | 1.55 | 2.11 | 3.63 | 2.54 | 3.75 | 7.85 | 9.00 | 1.41 | 2.90 | 5.30 | 18.63 | — |